An Introduction to Epilepsy
Epilepsy is one of the most common neurological disorders, affecting around 50 million people worldwide. Advances in epilepsy imaging and treatment (e.g. ablative and neurostimulation procedures, and new antiepileptic drugs) have decreased seizure frequency and severity. Yet unmet needs remain with approximately 30% of people with epilepsy refractory to pharmacotherapies. Novel therapeutic targets include AMPA receptors, potassium channels and synaptic vesicle protein 2A. Ongoing developments and improved understanding of the genetics of epilepsy subtypes may provide patient-specific solutions.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Barbara Jobst, AES 2021: Disrupting Disparities Project – Addressing Gaps in Epilepsy Care
In conjunction with the American Epilepsy Society (AES), we had the great pleasure of meeting with Barbara Jobst (Chair, Council of Education, American Epilepsy Society, USA) to discuss the Disrupting Disparities project which aims to improve outcomes for underserved people with epilepsy (PWE) by improving the epilepsy clinical knowledge of the non-specialist epilepsy care workforce, […]
Kimford Meador, AAN 2021: Fetal Antiseizure Medication in Pregnant Women with Epilepsy
It was a great pleasure to meet with Kimford Meador (Stanford University, Stanford, CA, USA) to discuss the effects and use of antiseizure medications during pregnancy, in women with epilepsy. The abstract entitled: ‘Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the MONEAD Study’ was presented at the American Academy of […]
Kimford Meador, AAN 2021: Preliminary findings of the MONEAD Study
It was a great pleasure to meet with Kimford Meador (Stanford University, Stanford, CA, USA) to discuss the aims, design and preliminary findings from the MONEAD study, and what these results mean for treatment of epilepsy in pregnant women. The abstract entitled: ‘Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the […]
Michael Sperling, AAN 2021: Post-hoc Analysis of Cenobamate for Uncontrolled Focal Seizures
We were delighted to speak with Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss the recent post-hoc analysis of cenobamate for uncontrolled focal seizures, and its intended place in the treatment landscape for epilepsy. The abstract entitled: ‘Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study’ […]
Addressing unmet needs to improve outcomes for people with epilepsy
Keep up to date on the latest developments by watching this webinar discussing key issues in the treatment and management of severe epilepsy, focussing on: The key unmet medical needs that still exist for people with severe epilepsy. How the latest clinical trial results support emerging therapeutic options to address these unmet needs. Challenges and insights that the COVID-19 pandemic has revealed about the diagnosis, treatment and management of people with epilepsy. Part 1: Watch the webinar with three internationally renowned experts discussing key issues in the treatment and management of severe epilepsy Watch Now Part 2: Watch the interview…
- Assess the main diagnostic approaches in epilepsy and the challenges that remain in the management and monitoring of the disease, particularly during the COVID-19 pandemic
- Recognize the key medical unmet needs that remain for people with epilepsy, especially with conditions that are often refractory to conventional anti-epileptic drugs, such as encephalopathic epilepsies
- Describe recent therapeutic developments in epilepsy, evaluate the supporting clinical evidence, and appreciate how they might impact quality of life beyond symptom control
Key developments in the diagnosis, treatment and understanding of childhood-onset, treatment-resistant epilepsies with Dr Antonietta Coppola & Dr Angel Aledo-Serrano
Watch this two-part activity discussing diagnostic and therapeutic advances in the field of childhood-onset treatment-resistant epilepsy from AES 2020 Part 1: Watch internationally renowned expert Dr Antonietta Coppola review key data from the conference focussing on genetic diagnosis and treatments Watch Now Part 2: Choose from two leading experts who discuss how data presented at the AES 2020 may affect daily practice Select An Interview
- Recognise the unmet needs and challenges that remain for people living with childhood-onset, treatment-resistant epilepsies.
- Understand the challenges that remain in the management and monitoring of the childhood-onset epilepsies, and be aware of the key diagnostic advances presented at AES 2020.
- Describe the key therapeutic developments for childhood-onset, treatment-resistant epilepsies presented at AES 2020.
Cenobamate for the Treatment of Focal Seizures
US Neurology. 2020;16(2):87–97 DOI: https://doi.org/10.17925/USN.2020.16.2.87
Epilepsy is a very common neurological disease, affecting more than 50 million people worldwide and 3.4 million people in the USA.1–3 Focal seizures, formerly partial-onset seizures, are the most common type, making up ≥60% of cases.4–6 Patients with epilepsy have an increased risk of morbidity and mortality, a decreased quality of life and are more likely […]
Cenobamate—The New Kid on the Block, Teaching More About Epilepsy Than Just Offering a New Treatment for Seizures
US Neurology. 2020;16(2):85–6 DOI: https://doi.org/10.17925/USN.2020.16.2.85
Dogma dictates that scientific literature should be couched in the third person, past tense. The idea is to obviate the potential to introduce personal bias that may accompany first person, present tense, which is creeping into modern scientific writing. This use of the first person, I am reliably told, followed wide adoption of blogging, in […]
Pat Penovich, AES 2020 – The Patient Experience With Diazepam Nasal Spray
It was a pleasure to talk to Pat Penovich (Minnesota Epilepsy Group, St. Paul, MN, USA) about the exit survey, of a Phase 3 study, assessing patient experience of using the diazepam nasal spray for seizure clusters. The abstract ‘Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!